Physician profile
Alaa Abousaif
NPI 1235124108
$74,728.89
in general payments reported to CMS, 2019-2025
52 companies · $13K in 2025
The $13K reported for 2025 was more than what 93% of Gastroenterology (Internal Medicine) providers received nationally (typical 2025 total: $636).
Payments by year
General and research payments by program year, as reported to CMS.
General payments by year: 2019: $10K · 2020: $4,065 · 2021: $4,217 · 2022: $3,452 · 2023: $3,405 · 2024: $36K · 2025: $13K.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $17K · Travel and Lodging: $16K · Food and Beverage: $14K · Consulting Fee: $4,890 · Education: $179.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $16,800.00 |
| Travel and Lodging | $16,485.83 |
| Food and Beverage | $14,407.30 |
| Consulting Fee | $4,890.00 |
| Education | $179.27 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Research payments are listed separately below. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Celltrion USA INC. | $20,696.47 | 2024-2025 | Zymfentra, Vegzelma |
| Phathom Pharmaceuticals, INC. | $19,322.09 | 2023-2025 | Voquezna |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $11,436.90 | 2019-2025 | Xifaxan, Trulance, Relistor |
| Takeda Pharmaceuticals U.S.A., INC. | $5,639.06 | 2019-2025 | Entyvio, Eohilia, Gattex |
| Abbvie INC. | $5,516.90 | 2019-2025 | Rinvoq, Skyrizi, Creon |
| Janssen Biotech, INC. | $1,701.52 | 2019-2025 | Tremfya, Stelara, Simponi |
| Celgene Corporation | $861.18 | 2021-2024 | Zeposia |
| Shionogi INC | $829.56 | 2019 | |
| Qol Medical, LLC | $829.37 | 2019-2025 | Sucraid, Sucraid |
| Pfizer INC. | $826.23 | 2019-2025 | |
| Madrigal Pharmaceuticals | $801.83 | 2024-2025 | Rezdiffra, Resmetirom |
| Ardelyx, INC. | $739.05 | 2022-2025 | Ibsrela |
| Genzyme Corporation | $582.59 | 2022-2025 | |
| Alfasigma USA, INC. | $536.81 | 2020 | |
| Gilead Sciences, INC. | $531.64 | 2019-2025 |
Show all 47 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Aimmune Therapeutics, INC. | $443.41 | 2024-2025 | Vowst, Zenpep |
| Ferring Pharmaceuticals INC. | $346.66 | 2019-2025 | Rebyota |
| Lilly USA, LLC | $297.11 | 2024-2025 | Omvoh |
| Intercept Pharmaceuticals, INC. | $275.48 | 2019-2025 | Ocaliva |
| Nestle Healthcare Nutrition INC. | $209.81 | 2021-2023 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $197.75 | 2023-2024 | Cyltezo |
| Ironwood Pharmaceuticals, INC | $193.05 | 2019-2025 | Linzess |
| Ipsen Biopharmaceuticals, INC | $187.10 | 2024-2025 | Iqirvo |
| Vivus LLC | $166.16 | 2024-2025 | Qsymia, Pancreaze |
| Redhill Biopharma INC. | $160.88 | 2020-2025 | Talicia |
| Amgen INC. | $152.90 | 2020-2021 | |
| Merck Sharp & Dohme LLC | $139.20 | 2019-2020 | |
| Daiichi Sankyo INC. | $131.14 | 2019-2022 | |
| Mirum Pharmaceuticals, INC. | $130.68 | 2025 | Livmarli |
| Fresenius Kabi USA, LLC | $120.36 | 2023-2024 | Idacio |
| Braintree Laboratories, INC. | $111.91 | 2021-2025 | Suflave, Sutab |
| Regeneron Healthcare Solutions, INC. | $93.64 | 2022-2025 | Dupixent |
| Albireo Pharma, INC. | $78.13 | 2024 | Iqirvo, Bylvay |
| Allergan, INC. | $59.83 | 2019-2020 | |
| Sandoz INC. | $51.49 | 2023-2025 | Hyrimoz |
| Exact Sciences Corporation | $50.58 | 2024 | Cologuard Collection Kit |
| Alnylam Pharmaceuticals INC. | $45.05 | 2022 | |
| Ucb, INC. | $38.62 | 2019 | |
| Evoke Pharma, INC. | $33.70 | 2022-2023 | Gimoti |
| Intra-Sana Laboratories | $29.68 | 2021 | |
| Boston Scientific Corporation | $27.81 | 2025 | Wavewriter Alpha Prime 16 |
| Shire North American Group INC | $23.89 | 2019 | |
| Dova Pharmaceuticals | $22.37 | 2019 | |
| Shield Therapeutics INC | $20.29 | 2022 | |
| Capsovision, INC. | $19.25 | 2023 | Capsocam Plus |
| W. L. Gore & Associates, INC. | $15.45 | 2022 | |
| Micro-Tech Endoscopy USA, INC. | $4.31 | 2022 |
5 companies reported research payments only; those appear in the research section below.
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
Research and ownership
$934.02 in research payments reported 2019-2025. Research payments are often institution-directed and tied to clinical trials: they are reported under a clinician's name but frequently go to a hospital or research organization, and usually reflect participation in medical research.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Alaa Abousaif listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.